bullish
Astellas FY17 Results and FY18e Guidance – No Major Surprise
112 Views04 May 2018 22:39
Astellas Pharma Inc (4503 JP) FY17 results
Xtandi (up 17% to ¥295b) and mirabegron (up 28% to ¥126b) ramp-up compensate for lackluster domestic...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Nippon Shinyaku Stock up 6% Provides Profit Booking Opportunity11 May 2018
- Shionogi FY17 Earnings - First Glance09 May 2018
- Nippon Shinyaku FY17 Earnings - First Glance09 May 2018
- Astellas FY17 Results and FY18e Guidance – No Major Surprise04 May 2018
- Japan Pharmaceuticals: FY17e Earnings Preview (II)27 Apr 2018
- Japan Pharma - FY17e Earnings Preview (I)24 Apr 2018
- Japan Pharmaceutical - Sector Overview29 Mar 2018
x